Table 6 Treatment-related adverse events in the two groups.
Adverse events, n (%) | Any Grade | ≥ 3 Grade | ||||
|---|---|---|---|---|---|---|
CT (n = 29) | ICT (n = 28) | P value | CT (n = 29) | ICT (n = 28) | P value | |
Leukopenia | 17 (58.62) | 12 (42.86) | 0.234 | 4 (13.79) | 2 (7.14) | 0.670 |
Neutropenia | 19 (65.52) | 13 (46.43) | 0.147 | 4 (13.79) | 2 (7.14) | 0.670 |
Anemia | 16 (55.17) | 12 (42.86) | 0.353 | 1 (3.45) | 2 (7.14) | 0.611 |
Thrombocytopenia | 20 (68.97) | 17 (60.71) | 0.514 | 4 (13.79) | 3 (10.71) | > 0.999 |
Liver dysfunction | 14 (48.28) | 12 (42.86) | 0.681 | 3 (10.34) | 2 (7.14) | > 0.999 |
Vomit | 14 (48.28) | 18 (64.29) | 0.223 | 1 (3.45) | 1 (3.57) | > 0.999 |
Immune-related pneumonia | 0 (0.00) | 1 (3.57) | 0.491 | 0 (0.00) | 0 (0.00) | > 0.999 |
Immune-related rash | 0 (0.00) | 3 (10.71) | 0.112 | 0 (0.00) | 0 (0.00) | > 0.999 |
Immune-related Hypogonadism | 0 (0.00) | 1 (3.57) | 0.491 | 0 (0.00) | 0 (0.00) | > 0.999 |
Fatigue | 12 (41.38) | 15 (53.57) | 0.357 | 0 (0.00) | 0 (0.00) | > 0.999 |
Diarrhoea | 3 (10.34) | 0 (0.00) | 0.237 | 1 (3.45) | 0 (0.00) | > 0.999 |
